Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s share price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.03 and traded as high as $0.03. Mateon Therapeutics shares last traded at $0.03, with a volume of 291,652 shares.
Mateon Therapeutics Trading Up 7.2 %
The business’s 50 day moving average is $0.04 and its 200 day moving average is $0.03.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Stories
- Five stocks we like better than Mateon Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Micron Stock Under $100: Seize the AI-Driven Upside
- 3 Tickers Leading a Meme Stock Revival
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- Low PE Growth Stocks: Unlocking Investment Opportunities
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
